Found: 17
Select item for more details and to access through your institution.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 68, doi. 10.1007/s10637-021-01156-9
- By:
- Publication type:
- Article
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 3, p. 803, doi. 10.1007/s10637-020-01047-5
- By:
- Publication type:
- Article
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
- Published in:
- AAPS Journal, 2020, v. 22, n. 4, p. 1, doi. 10.1208/s12248-020-00463-y
- By:
- Publication type:
- Article
Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis.
- Published in:
- Proteomics, 2003, v. 3, n. 7, p. 1162, doi. 10.1002/pmic.200300437
- By:
- Publication type:
- Article
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 7, p. 1495, doi. 10.1111/bcp.13920
- By:
- Publication type:
- Article
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
- Published in:
- Neuro-Oncology, 2013, v. 15, n. 6, p. 759, doi. 10.1093/neuonc/nos315
- By:
- Publication type:
- Article
Therapeutically-induced stable disease in oncology early clinical trials.
- Published in:
- PLoS ONE, 2020, v. 15, n. 5, p. 1, doi. 10.1371/journal.pone.0233882
- By:
- Publication type:
- Article
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 4, p. 1130, doi. 10.1002/cpt.3386
- By:
- Publication type:
- Article
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 3, p. 616, doi. 10.1002/cpt.1964
- By:
- Publication type:
- Article
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
- Published in:
- European Journal of Clinical Pharmacology, 2010, v. 66, n. 8, p. 775, doi. 10.1007/s00228-010-0841-2
- By:
- Publication type:
- Article
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 3, p. 239, doi. 10.1007/s00280-023-04510-1
- By:
- Publication type:
- Article
Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 6, p. 997, doi. 10.1007/s00280-021-04353-8
- By:
- Publication type:
- Article
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 4, p. 837, doi. 10.1007/s00280-015-2697-8
- By:
- Publication type:
- Article
Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug-Drug Interactions.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 10, p. 1188, doi. 10.1177/0091270009358709
- By:
- Publication type:
- Article